Ernst Wagner

Bioinspired chemical evolution of nucleic acid nanomedicines.



Munich – Germany


Ernst Wagner, 58, PhD in chemistry in 1985 from TU Vienna, habilitation in 1994 from Vienna U Medical Faculty, full professor at Ludwig-Maximilians-Universitaet (LMU) Munich since 2001, Area Coordinator of Biomedical Nanotechnologies and Executive Board Member of Excellence Cluster Nanosystems Initiative Munich (NIM), has authored ≥425 publications (h-index 76) and ≥20 patents.

He is Editor-in Chief of The Journal of Gene Medicine, an Editor of Pharmaceutical Research, board member of the German Society for Gene Therapy, and Committee member of the ASGCT. He was guest professor at Fudan U 2012-2013, Sichuan U 2014-2017, Utrecht U 1996, and is elected member of the Controlled Release Society (CRS) College of Fellows, and Academician of the European Academy of Sciences.

For now 30 years he has contributed to design of synthetic carriers for drugs, proteins and genes. As Group Leader (1988-1992) at the Institute of Molecular Pathology, Vienna, he developed synthetic virus-like gene transfer systems, including a series of patents on receptor-targeted polyplexes, endosomal escape agents, or adenovirus-enhanced transferrinfection (AVET). In his former function as Director for Cancer Vaccines at Boehringer Ingelheim Austria, this system was applied for the development of the first-in-world polymer-based clinical gene therapy study in 1994.